Paradigm CEO Paul Rennie to transition to Non-Exec Chairman
Filed with ASX · · 2 pages · English
Paradigm Biopharmaceuticals Ltd (ASX: PAR) (“Paradigm” or “the Company”), a Phase 3 clinical stage biopharmaceutical company focussed on repurposing existing molecules for new indications with unmet clinical needs, wishes to inform the market that its CEO, Paul Rennie, is transitioning from his executive role (Managing Director) to a non-executive role (Chairman) with immediate effect. Mr Rennie f
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Paradigm cleared for phase 3 Trial by US FDA
- Phase 2 Synovial Fluid Biomarker Study Update
- Positive top-line results from preclinical study in ARDS
- First MPS-VI patient dosed under Phase 2 trial in Brazil
- Paradigm receives feedback from US FDA on ind submission
Later from Paradigm Biopharmaceuticals
- Preliminary Results from Phase 2 MPS I Study
- PAR reports postive topline results in heart failure model
- Paradigm treats first subjects in phase 3 trial of Zilosul
- Paradigm 1HY22 Key Activity Highlights
- S&P DJI Announces March 2022 Quarterly Rebalance
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals